leadf
logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sci PLC - Total Voting Rights

RNS Number : 8188U
Tiziana Life Sciences PLC
31 July 2020
 

Tiziana Life Sciences plc

("Tiziana" or the "Company")

 Total Voting Rights

LondonNew York, 31 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today updated its total voting rights disclosure position.

 

ATM Issues during July 2020

 

During the calendar month of July, the Company issued a total of 2,043,000 ordinary shares under the Company's ATM sales agreement announced on 15 April 2020 to meet sales of a total of 408,600 ADSs under the ATM sales agreement, totaling gross proceeds of $4,371,289 in the month of July 2020. Those ordinary shares were admitted to trading on AIM under the Company's "US ADSs ATM Placing Scheme" block listing.

 

Total Voting Rights

 

In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, it has a single class of shares in issue being Ordinary Shares, the total number of Ordinary Shares in issue will be 168,540,593. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

 

The figure of 168,540,593 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered Foralumab for Crohn's Disease and nasally administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further enquiries:

 

United Kingdom:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder 

+44 (0)20 7495 2379

 

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner 

 

 

+44 (0)20 7213 0880

Optiva Securities Limited (Broker)

Robert Emmet

+44 (0)20 3981 4173

 

United States:

Investors
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
dave@redchip.com

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVREALXFDADEEFA

Quick facts: Tiziana Life Sciences PLC

Price: 141

Market: AIM
Market Cap: £269.54 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Tiziana Life Sciences to fast-track its human coronavirus trials for...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) chairman Gabriele Cerrone speaks to Proactive London's Andrew Scott after announcing they're soon to kick off a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. He says it's due to start in the next...

2 days, 2 hours ago